Black Rock Inc. Adverum Biotechnologies, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.75 - $1.26 $81 - $136	-108 Reduced 0.01%	1,401,180 $1.05 Million
Q3 2023 Nov 13, 2023	SELL	$1.5 - $2.33 $3,484 - $5,412	-2,323 Reduced 0.17%	1,401,288 $2.1 Million
Q2 2023 Aug 11, 2023	SELL	$0.68 - $1.59 $431,078 - $1.01 Million	-633,939 Reduced 31.11%	1,403,611 $2.23 Million
Q1 2023 May 12, 2023	SELL	$0.62 - $0.85 $221,498 - $303,667	-357,256 Reduced 14.92%	2,037,550 $1.47 Million
Q4 2022 Feb 13, 2023	SELL	$0.54 - $10.3 $434,116 - $8.28 Million	-803,919 Reduced 25.13%	2,394,806 $1.39 Million
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $120,113 - $1.21 Million	-125,118 Reduced 3.76%	3,198,725 $3.04 Million
Q2 2022 Aug 12, 2022	SELL	$0.81 - $1.34 $3.23 Million - $5.35 Million	-3,991,696 Reduced 54.56%	3,323,843 $3.99 Million
Q1 2022 May 12, 2022	SELL	$1.23 - $1.95 $38,478 - $61,001	-31,283 Reduced 0.43%	7,315,539 $9.58 Million
Q4 2021 Feb 10, 2022	SELL	$1.74 - $2.4 $153,558 - $211,804	-88,252 Reduced 1.19%	7,346,822 $12.9 Million
Q3 2021 Nov 09, 2021	SELL	$2.08 - $3.6 $1.14 Million - $1.97 Million	-548,048 Reduced 6.87%	7,435,074 $16.1 Million
Q2 2021 Aug 11, 2021	BUY	$3.36 - $10.56 $26.8 Million - $84.3 Million	7,983,122 New	7,983,122 $27.9 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.